Health A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH James Pereira Jul 19, 2023 Exton, Pennsylvania, July 18, 2023 (GLOBE NEWSWIRE) -- Data from the Centers for Disease Control & Prevention… Read More...
Health NAFLD and T2DM Bodes Higher Risk of Liver Decompensation, Cancer James Pereira Jul 12, 2023 Patients… Read More...
Health CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease James Pereira Jul 11, 2023 PRINCETON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment… Read More...
Health Non-alcoholic Steatohepatitis Therapeutics Market to Grow at a CAGR of 13.6% during the 2022 to 2031… James Pereira Jul 8, 2023 Wilmington, Delaware, United States, July 07, 2023 (GLOBE NEWSWIRE) -- The global non-alcoholic steatohepatitis… Read More...
Health ICER MIDWEST CEPAC WORKS TO KEEP UP WITH WELL-INFORMED NASH PATIENT ADVOCATES James Pereira May 2, 2023 <!-- Name:DistributionId Value:8829412 --> <!--… Read More...
Health PATIENT GROUPS DECLARE ICER REVIEW OF NASH MEDICATIONS CAUSES MORE UNCERTAINTY AND CONTROVERSIES… James Pereira Apr 28, 2023 <!-- Name:DistributionId Value:8828197 --> <!--… Read More...
Health Time-Restricted Eating No Better Than Cutting Calories Alone for NAFLD James Pereira Mar 17, 2023 Adding time… Read More...
Health DelveInsight Evaluates a Robust Nonalcoholic Fatty Liver Disease Pipeline as 110+ Influential Pharma… James Pereira Jan 2, 2023 New York, USA, Jan. 02, 2023 (GLOBE NEWSWIRE) -- DelveInsight Evaluates a Robust Nonalcoholic Fatty Liver Disease… Read More...
Health Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program James Pereira Dec 22, 2022 $259 Million in Equity Securities Sales and $50 Million in Additional Debt Financing CapacityMadrigal intends to submit… Read More...
Health Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of… James Pereira Dec 19, 2022 CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage… Read More...